Alkermes and Janssen enter arbitration over nanocrystal tech

Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Alkermes settles with Amneal over opioid dependence treatment

31 July 2019 Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.

Americas

LSPN 19: Two bites at the apple here to stay, says Alkermes director

26 April 2019 Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board, effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Alkermes and Janssen enter arbitration over nanocrystal tech

More on this story

Editor's picks

Editor's picks

More features